News
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.
Texas Sues Eli Lilly: 'Big Pharma Compromised Medical Decision-Making'
Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its most profitable drugs, including the high-demand GLP-1 medications Mounjaro and Zepbound that are used for weight loss and diabetes treatment.
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...
Investor's Business Daily on MSN27m
Eli Lilly Hikes UK Mounjaro Price By Up To 170% As Trump Pressure Mounts
Eli Lilly said Thursday it will hike the UK list price of its diabetes and weight-loss drug Mounjaro by up to 170%.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Trump administration demands lower prices in the U.S., forcing the pharmaceutical company to raise them in other markets ...
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback